Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2006-01-31
2006-01-31
Andres, Janet (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085700, C424S085500, C424S085400, C424S085100, C514S002600, C530S351000, C530S350000, C530S399000
Reexamination Certificate
active
06991785
ABSTRACT:
The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon-β and its muteins such as IFN-βser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and/or autoimmune disorders such as Sjogren's disorder.
REFERENCES:
patent: 4462985 (1984-07-01), Cummins
patent: 4479932 (1984-10-01), Bodor
patent: 4497795 (1985-02-01), Cummins
patent: 4746508 (1988-05-01), Carey et al.
patent: 4820514 (1989-04-01), Cummins
patent: 4820515 (1989-04-01), Cummins
patent: 4857316 (1989-08-01), Eppstein
patent: 5017371 (1991-05-01), Cummins
patent: 5019382 (1991-05-01), Cummins
patent: 5145677 (1992-09-01), von Eichborn et al.
patent: 5215741 (1993-06-01), Young et al.
patent: 5482706 (1996-01-01), Igari et al.
patent: 5514670 (1996-05-01), Friedman et al.
patent: 5624898 (1997-04-01), Frey, II
patent: 5676942 (1997-10-01), Testa et al.
patent: 5817307 (1998-10-01), Cummins
patent: 5824300 (1998-10-01), Cummins
patent: 5830456 (1998-11-01), Cummins
patent: 5846526 (1998-12-01), Cummins
patent: 5853763 (1998-12-01), Tice et al.
patent: 5882640 (1999-03-01), Cummins
patent: 5910304 (1999-06-01), Cummins
patent: 6036949 (2000-03-01), Richards et al.
patent: 6048843 (2000-04-01), Tóth
patent: 6060450 (2000-05-01), Soos et al.
patent: 6127332 (2000-10-01), Goelz et al.
patent: 6361769 (2002-03-01), Tovey
patent: 6372218 (2002-04-01), Cummins
patent: 0 504 263 (1992-09-01), None
patent: 7041428 (1995-02-01), None
patent: 1139444 (1985-02-01), None
patent: WO 91/07947 (1991-06-01), None
patent: WO 97/41884 (1997-11-01), None
patent: WO 00/33814 (2000-06-01), None
patent: WO 00/44350 (2000-08-01), None
patent: WO 00/44350 (2000-08-01), None
Sperber, S.J., et al. J. Infectious Diseases 1998, vol. 158(1), pp. 166-175.
Sperber, S.J., et al. Archives of Otolarygology- Head and Neck Surgery 1992, vol. 118(9), pp. 933-936.
Barbaro et al. (1999) “Intravenous Recombinant Interferon-Beta versus Interferon-Alpha-2b and Ribavirin in Combination for Short-Term Treatment of Chronic Hepatitis C Patients Not Responding to Interferon-Alpha,”Scand. J. Gastroenterol. 34(9): 928-933.
Bocci et al. (1988) “The Lymphatic Route. V. Distribution of Human Natural Interferon-β in Rabbit Plasma and Lymph,”Journal of Interferon Research8(5): 633-640.
Chien et al. (1989) “Nasal Systemic Drug Delivery,”Modern Pharmaceutics39: 18-19, 44-49, 56-59, 82-85, 292-293.
Cui (2000) “A Plasmid Construct Encoding Murine Interferon Beta Antagonizes the Replication of Herpes Simplex Virus Type I In Vitro and In Vivo,”J. Neuroimmunology108:92-102.
Eppstein et al. (1988) “Alternative Delivery Systems for Peptides and Proteins as Drugs,”CRC Critical Reviews in Therapeutic Drug Carrier Systems5(2): 99-139.
Geiger (1997) “Interferon-γ Protects against Herpes Simplex Virus Type 1-Mediated Neuronal Death,”Virology238: 189-197.
Gopinath et al. (1978) “Target Site of Intranasally Sprayed Substances and Their Transport Across the Nasal Mucosa: A New Insight into the Intranasal Route of Drug-Delivery,”Current Therapeutic Research23(5): 596-607.
Kakizaki et al. (1999) “Evaluation of Twice-Daily Administration of Interferon-β for Chronic Hepatitis C,”J. Viral Hepatitis6: 315-319.
Kida et al. (1993) “CSF Drains Directly from the Subarachnoid Space into Nasal Lymphatics in the Rat. Anatomy, Histology and Immunological Significance,”Neuropathology and Applied Neurobiology19: 480-488.
Lee et al. (1988) “Intranasal Delivery of Proteins and Peptides,”BioPharm. pp. 30-37.
Leib et al. (1999) “Interferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex Viruses In Vivo,”J. Exp. Med. 189: 663-672.
Minagawa et al. (1997) “Suppression of Infectious Virus Spread and Corneal Opacification by the Combined Use of Recombinant Interferon Beta and Interleukin-10 Following Corneal Infection with Herpes Simplex Virus-1 in Mice,”Antiviral Research36: 99-105.
Pelidou (2000) “Intranasal Administration of Recombinant Mouse Interleukin-12 Increases Inflammation and Demyelinaton in Chronic Experimental Autoimmune Neuritis in Lewis Rats,”Scand. J. Immunol. 51: 25-35.
Peridou et al. (2000) “Enhancement of Acute Phase and Inhibition of Chronic Phase of Experimental Autoimmune Neuritis in Lewis Rats by Intranasal Administration of Recombinant Mouse Interleukin 17: Potential Immunoergulatory Role,”Experimental Neurology163: 165-172.
Ship et al. (1999) “Treatment of Primary Sjögren's Syndrome with Low-Dose Natural Human Interferon-α Administered by the Oral Mucosal Route: A Phase II Clinical Trial,”J. Interferon and Cytokine Res. 19: 943-951.
Smith et al. (1987) “Intranasally Administered Alpha/Beta Interferon Prevents Extension of Mouse Hepatitis Virus, Strain JHM, into the Brains of BALB/cByJ Mice,”Antiviral Research8: 239-245.
Thorne et al. (date unknown) “Quantitative Assessment of Protein Transport to the Rat Olfactory Bulb Following Intranasal Administration: Implications for Drug Delivery,”Paper for Dept. of Neurology, St. Paul Ramsey Medical Ctr. (20 pages).
Xiao et al. (1998) “Suppression of Acute and Protracted-Relapsing Experimental Allergic Encephalomyelitis by Nasal Administration of Low-Dose IL-10 in Rats,”J. Neuroimmuno. 84: 230-237.
Thorne, R.G., “Delivery of Neurotrophic Factors to the Central Nervous System,”Clin. Pharmacokinet, 2001, pp. 907-946, vol. 40(12).
Thorne, R.G., “Delivery of Insulin-Like Growth Factor-1 to the Brain and Spinal Cord Along Olfactory and Trigeminal Pathways Following Intranasal Administration: A Noninvasive Method for Bypassing the Blood-Brain Barrier,”Soc. Neurosci., 2000, Abstract No. 26(2).
Andres Janet
Austin James
Chiron Corporation
Harbin Alisa A.
Silver Joel B.
LandOfFree
Method for administering a cytokine to the central nervous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for administering a cytokine to the central nervous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for administering a cytokine to the central nervous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3552663